Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23924689 | 0.82 | ALDH1A1 (0.35) | ALDH1A1TSHRCYP1A2ADORA3DYRK1A | |
| SCHEMBL23951052 | 0.80 | IDO1 (0.34) | ALDH1A1TSHRCYP1A2ADORA3DYRK1A | |
| SCHEMBL23924759 | 0.77 | EGFR (0.46) | ALDH1A1TSHRCYP1A2ADORA3DYRK1A | |
| SCHEMBL19127706 | 0.70 | CYP3A4 (0.47) | ALDH1A1TSHRCYP1A2BRAFALOX15 | |
| SCHEMBL23235317 | 0.70 | MEN1 (0.33) | CYP1A2 | |
| SCHEMBL1443111 | 0.69 | TRPM8 (0.65) | ALDH1A1 | |
| SCHEMBL23235301 | 0.66 | CYP1A2 (0.48) | TSHRCYP1A2ADORA3HSD17B10 | |
| SCHEMBL30675605 | 0.65 | L3MBTL1 (0.53) | CYP1A2ADORA3BRAF | |
| SCHEMBL3934366 | 0.65 | CYP1A2 (0.40) | ALDH1A1TSHRCYP1A2ADORA3IDO1 | |
| SCHEMBL38651185 | 0.64 | ALDH1A1 (0.57) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11970511-B2 | Tetrahydropyran-based thiodisaccharide mimics as Galectin-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-30 | — | — | US | disclosed |
| EP-3807290-B1 | TETRAHYDROPYRAN-BASED THIODISACCHARIDE MIMICS AS GALECTIN-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-03-30 | — | — | EP | disclosed |
| US-20210323991-A1 | TETRAHYDROPYRAN-BASED THIODISACCHARIDE MIMICS AS GALECTIN-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-21 | — | — | US | disclosed |
| US-20210323991-A1 | TETRAHYDROPYRAN-BASED THIODISACCHARIDE MIMICS AS GALECTIN-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11970511-B2 | Tetrahydropyran-based thiodisaccharide mimics as Galectin-3 inhibitors | LGALS3, LGALS1, LGALS3BP | ALDH1A1 2364/4885TSHR 724/4885CYP1A2 3883/4885 |
| US-20210323991-A1 | TETRAHYDROPYRAN-BASED THIODISACCHARIDE MIMICS AS GALECTIN-3 INHIBITORS | LGALS3, LGALS1, LGALS3BP | ALDH1A1 2364/4885TSHR 724/4885CYP1A2 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.